FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Belshe

Research Profile

Chemicals & Drugs

Disorders

Human Influenza

Procedures

Living Beings

Concepts & Ideas

Immunization Schedule

Co-author Network

Publications

TOP 3
Ki Soo Kang; Sang Doo Kim; Naeun Lee; Subhasis Mohanty; Ruth R Montgomery; Albert C Shaw; Min Sun Shin; Yinyi Yu; Robert B Belshe; Insoo Kang
An altered relationship of influenza vaccine-specific IgG responses with T cell immunity occurs with aging in humans.
David I Bernstein; Carolyn D Deal; Gary Dubin; Marian G Ewell; Thomas C Heineman; Edward W Hook; Myron J Levin; Anna Wald; Peter A Wolff; Abbie R Bellamy; Robert B Belshe
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.
John Lok Man Law; Charles M Rice; Deanna M Santer; D Lorne Tyrrell; Takaji Wakita; Jason Wong; Sergio Abrignani; Robert B Belshe; Jens Bukh; Chao Chen; Sharon E Frey; Darren Hockman; Christopher T Jones; Michael Houghton
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Belshe (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ki Soo Kang; Sang Doo Kim; Naeun Lee; Subhasis Mohanty; Ruth R Montgomery; Albert C Shaw; Min Sun Shin; Yinyi Yu; Robert B Belshe; Insoo Kang
An altered relationship of influenza vaccine-specific IgG responses with T cell immunity occurs with aging in humans.
Clinical immunology (Orlando, Fla.) 2013;147(2):79-88.
2013: David I Bernstein; Carolyn D Deal; Gary Dubin; Marian G Ewell; Thomas C Heineman; Edward W Hook; Myron J Levin; Anna Wald; Peter A Wolff; Abbie R Bellamy; Robert B Belshe
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013;56(3):344-51.
2013: John Lok Man Law; Charles M Rice; Deanna M Santer; D Lorne Tyrrell; Takaji Wakita; Jason Wong; Sergio Abrignani; Robert B Belshe; Jens Bukh; Chao Chen; Sharon E Frey; Darren Hockman; Christopher T Jones; Michael Houghton
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.
PloS one 2013;8(3):e59776.
2012: Seth Toback; Myron J Levin; Christopher S Ambrose; Robert B Belshe; Stan L Block; Judith Falloon
Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.
Expert review of vaccines 2012;11(11):1293-303.
2012: Sharon E Frey; Michael A Gerber; Heather Hill; Harry L Keyserling; Flor M Munoz; Diana L Noah; Allison C Ross; Richard E Rupp; Christine B Turley; Patricia L Winokur; Mark Wolff; David I Bernstein; Gretchen Cress; Robert B Belshe
Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
The Journal of infectious diseases 2012;206(6):828-37.
2012: Christine M Hughes; Kevin L Karem; Frances K Newman; Victoria A Olson; Scott K Smith; Lihan Yan; Robert B Belshe; Whitni B Davidson; Sharon E Frey; Robert C Holman; Inger K Damon
Analysis of variola and vaccinia virus neutralization assays for smallpox vaccines.
Clinical and vaccine immunology : CVI 2012;19(7):1116-8.
2012: Stan L Block; Filip Dubovsky; Judith Falloon; Jeffrey A Hirschfield; Leonard R Krilov; Tingting Yi; Robert B Belshe
Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.
The Pediatric infectious disease journal 2012;31(7):745-51.
2012: Robert B Belshe
A century of influenza prevention in St. Louis.
Missouri medicine 2012;109(2):119-23.
2012: Natalie Pica; Cheryl R Stein; Gene S Tan; Taia T Wang; Jens Wrammert; David Banach; Robert B Belshe; Dirk Eggink; Adolfo García-Sastre; Hai Rong; Florian Krammer; Jens C Krause; Jad Maamary; Thomas Moran; Peter Palese
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.
Proceedings of the National Academy of Sciences of the United States of America 2012;109(7):2573-8.
2012: Christopher S Ambrose; Robert B Belshe
Influenza vaccine in young children.
The New England journal of medicine 2012;366(4):383; author reply 383-4.
2011: Daniel F Hoft; Kathleen Lottenbach; Frances Newman; Isaac G Sakala; Charles T Spencer; Steven M Truscott; Shewangizaw Worku; Getahun Abate; Edwin L Anderson; Elizabeth Babusis; David I Bernstein; C Buddy Creech; Kathryn M Edwards; Michael A Gerber; Irene Graham; Robert B Belshe
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children.
The Journal of infectious diseases 2011;204(6):845-53.
2011: Christopher S Ambrose; Myron J Levin; Robert B Belshe
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults.
Influenza and other respiratory viruses 2011;5(2):67-75.
2011: Robert B Belshe; Sharon E Frey; Irene Graham; Mark MULLIGAN; Srilatha Edupuganti; Lisa A Jackson; Anna Wald; Gregory Poland; Robert Jacobson; Harry Keyserling; Paul Spearman; Heather Hill; Mark Wolff
Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
The Journal of infectious diseases 2011;203(5):666-73.
2011: Keith Meyer; Arup Banerjee; Robert B Belshe; Sharon E Frey; Ranjit Ray
A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection.
PloS one 2011;6(8):e23699.
2010: Ranjit Ray; Keith Meyer; Arup Banerjee; Arnab Basu; Stephen Coates; Sergio Abrignani; Michael Houghton; Sharon E Frey; Robert B Belshe
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.
The Journal of infectious diseases 2010;202(6):862-6.
2010: Robert B Belshe
The need for quadrivalent vaccine against seasonal influenza.
Vaccine 2010;28 Suppl 4():D45-53.
2010: Gerry Oster; Derek Weycker; John Edelsberg; Kristin L Nichol; Jerome O Klein; Robert B Belshe
Benefits and risks of live attenuated influenza vaccine in young children.
The American journal of managed care 2010;16(9):e235-44.
2010: Christopher S Ambrose; Xionghua Wu; Robert B Belshe
The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination.
The Pediatric infectious disease journal 2010;29(9):806-11.
2010: Sharon E Frey; Michael Houghton; Stephen Coates; Sergio Abrignani; David Chien; Domenico Rosa; Piero Pileri; Ranjit Ray; Adrian M Di Bisceglie; Paola Rinella; Heather Hill; Mark C Wolff; Viola Schultze; Jang H Han; Bruce Scharschmidt; Robert B Belshe
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.
Vaccine 2010;28(38):6367-73.
2010: Chin-Fen Yang; Robert B Belshe; George W Kemble; Eyun Song; Dan Ye; Brandon Liang; Tingting Yi; Christopher S Ambrose; Kathleen L Coelingh; Robert E Walker
Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine.
Vaccine 2010;28(31):5128-34.
2010: Larry R Smith; Mary K Wloch; Ming Ye; Luane R Reyes; Souphaphone Boutsaboualoy; Casey E Dunne; Jennifer A Chaplin; Denis Rusalov; Alain Rolland; Cindy L Fisher; Mohamed S Al-Ibrahim; Martin L Kabongo; Roy Steigbigel; Robert B Belshe; Ernest R Kitt; Alice H Chu; Ronald B Moss
Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
Vaccine 2010;28(13):2565-72.
2010: Alexander Panda; Qian Feng; Subhasis Mohanty; David van Duin; Frances K Newman; Lin Zhang; Shu Chen; Virginia Towle; Robert B Belshe; Erol Fikrig; Heather G Allore; Ruth R Montgomery; Albert C Shaw
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response.
Journal of immunology (Baltimore, Md. : 1950) 2010;184(5):2518-27.
2010: Robert B Belshe; Kathleen L Coelingh; Christopher S Ambrose; Jennifer C Woo; Xionghua Wu
Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
Vaccine 2010;28(9):2149-56.
2010: Rafael A Medina; Balaji Manicassamy; Silke Stertz; Christopher W Seibert; Hai Rong; Robert B Belshe; Sharon E Frey; Christopher F Basler; Peter Palese; Adolfo García-Sastre
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus.
Nature communications 2010;1():28.
2009: Inger K Damon; Whitni B Davidson; Christine M Hughes; Victoria A Olson; Scott K Smith; Robert C Holman; Sharon E Frey; Frances Newman; Robert B Belshe; Lihan Yan; Kevin L Karem
Evaluation of smallpox vaccines using variola neutralization.
The Journal of general virology 2009;90(Pt 8):1962-6.
2009: Robert B Belshe
Implications of the emergence of a novel H1 influenza virus.
The New England journal of medicine 2009;360(25):2667-8.
2009: Gallen B Triana-Baltzer; Larisa V Gubareva; Alexander I Klimov; David F Wurtman; Ronald B Moss; Maria Hedlund; Jeffrey L Larson; Robert B Belshe; Fang Fang
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.
PloS one 2009;4(11):e7838.
2008: Robert B Belshe
An introduction to influenza: lessons from the past in epidemiology, prevention, and treatment.
Managed care (Langhorne, Pa.) 2008;17(10 Suppl 10):2-7.
2008: Robert B Belshe; Christopher S Ambrose; Tingting Yi
Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.
Vaccine 2008;26 Suppl 4():D10-6.
2008: Bryan R Luce; Kristin L Nichol; Robert B Belshe; Kevin D Frick; Su Xia Li; Audra Boscoe; Matthew Rousculp; Parthiv Mahadevia
Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Vaccine 2008;26(23):2841-8.
2008: David I Bernstein; Kathryn M Edwards; Cornelia L Dekker; Robert B Belshe; Helen K B Talbot; Irene L Graham; Diana L Noah; Fenhua He; Heather Hill
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
The Journal of infectious diseases 2008;197(5):667-75.
2007: Sharon E Frey; Frances K Newman; Jeffrey S Kennedy; Vera Sobek; Irene Bosch; Heather Hill; Lihan K Yan; Paul Chaplin; Jens Vollmar; Bernard R Chaitman; Robert B Belshe
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.
Vaccine 2007;25(51):8562-73.
2007: Robert B Belshe
Translational research on vaccines: influenza as an example.
Clinical pharmacology and therapeutics 2007;82(6):745-9.
2007: Robert B Couch; Patricia L Winokur; Rebecca Brady; Robert B Belshe; Wilbur H Chen; Thomas R Cate; Bryndis Sigurdardottir; Amy Hoeper; Irene L Graham; Robert Edelman; Fenhua He; Diane Nino; Jose Capellan; Fred Ruben
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects.
Vaccine 2007;25(44):7656-63.
2007: Peter F Wright; Ruth A Karron; Robert B Belshe; Jian R Shi; Valerie B Randolph; Peter L Collins; Alice F O'Shea; William C Gruber; Brian Murphy
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
Vaccine 2007;25(42):7372-8.
2007: Robert B Belshe; Frances K Newman; Ken Wilkins; Irene L Graham; Elizabeth Babusis; Marian Ewell; Sharon E Frey
Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults.
Vaccine 2007;25(37-38):6755-63.
2007: Robert B Belshe
The burden of influenza and strategies for prevention.
Managed care (Langhorne, Pa.) 2007;16(8 Suppl 8):2-6; discussion 17-9.
2007: Steven J Lawrence; Kathleen R Lottenbach; Frances K Newman; R Mark L Buller; Clifford J Bellone; John J Chen; Gary cohen; Roselyn J Eisenberg; Robert B Belshe; Samuel L Stanley; Sharon E Frey
Antibody responses to vaccinia membrane proteins after smallpox vaccination.
The Journal of infectious diseases 2007;196(2):220-9.
2007: Samuel L Stanley; Sharon E Frey; Patricia Taillon-Miller; Jianhua Guo; Raymond D Miller; Daniel C Koboldt; Michael Elashoff; Ryan Christensen; Nancy L Saccone; Robert B Belshe
The immunogenetics of smallpox vaccination.
The Journal of infectious diseases 2007;196(2):212-9.
2007: Peter F Wright; Anne M Deatly; Ruth A Karron; Robert B Belshe; Jian R Shi; William C Gruber; Yuwei Zhu; Valerie B Randolph
Comparison of results of detection of rhinovirus by PCR and viral culture in human nasal wash specimens from subjects with and without clinical symptoms of respiratory illness.
Journal of clinical microbiology 2007;45(7):2126-9.
2007: David van Duin; Heather G Allore; Subhasis Mohanty; Sandra Ginter; Frances K Newman; Robert B Belshe; Ruslan Medzhitov; Albert C Shaw
Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults.
The Journal of infectious diseases 2007;195(11):1590-7.
2007: Robert B Belshe; Kathryn M Edwards; Timo Vesikari; Steven V Black; Robert E Walker; Mitchell Ann M Hultquist; George W Kemble; Edward M Connor
Live attenuated versus inactivated influenza vaccine in infants and young children.
The New England journal of medicine 2007;356(7):685-96.
2006: Majid Laassri; Kathleen Lottenbach; Robert B Belshe; Margaret B Rennels; Stanley Plotkin; Konstantin Chumakov
Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
The Journal of infectious diseases 2006;193(10):1344-9.
2006: Shabir A Madhi; Clare Cutland; Yuwei Zhu; Jill Hackell; Frances K Newman; Nigel Blackburn; Brian Murphy; Robert B Belshe; Ruth A Karron; Anne M Deatly; William C Gruber; David I Bernstein; Peter F Wright
Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
Vaccine 2006;24(13):2432-9.
2005: Majid Laassri; Kathleen Lottenbach; Robert B Belshe; Mark Wolff; Margaret B Rennels; Stanley Plotkin; Konstantin Chumakov
Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
The Journal of infectious diseases 2005;192(12):2092-8.
2005: Robert B Belshe
The origins of pandemic influenza--lessons from the 1918 virus.
The New England journal of medicine 2005;353(21):2209-11.
2005: Getahun Abate; Joy Eslick; Frances K Newman; Sharon E Frey; Robert B Belshe; Thomas P Monath; Daniel F Hoft
Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions.
The Journal of infectious diseases 2005;192(8):1362-71.
2005: Majid Laassri; Eugenia Dragunsky; Joan C Enterline; Tatyana P Eremeeva; Olga E Ivanova; Kathleen Lottenbach; Robert B Belshe; Konstantin Chumakov
Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization.
Journal of clinical microbiology 2005;43(6):2886-94.
2005: Ruth A Karron; Peter F Wright; Robert B Belshe; Bhagvanji Thumar; Roberta Casey; Frances K Newman; Fernando P Polack; Valerie B Randolph; Anne M Deatly; Jill Hackell; William C Gruber; Brian Murphy; Peter L Collins
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
The Journal of infectious diseases 2005;191(7):1093-104.
2005: Michael R Betts; Barbara Exley; David A Price; Anju Bansal; Zenaido Tres Camacho; Vanessa Teaberry; Sadie M West; David R Ambrozak; Georgia D Tomaras; Mario Roederer; J. Michael Kilby; Jim Tartaglia; Robert B Belshe; Feng Gao; Daniel C Douek; Kent J Weinhold; Richard A Koup; Paul A Goepfert; Guido Ferrari
Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(12):4512-7.
2004: Robert B Belshe; Frances K Newman; Edwin L Anderson; Peter F Wright; Ruth A Karron; Sharon J Tollefson; Frederick W Henderson; H Cody Meissner; Shabir A Madhi; Don Roberton; Helen Marshall; Richard Loh; Peter Sly; Brian Murphy; Joanne M Tatem; Valerie B Randolph; Jill Hackell; William C Gruber; Theodore F Tsai
Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
The Journal of infectious diseases 2004;190(12):2096-103.
2004: Daniel F Hoft; Robert B Belshe
The genetic archaeology of influenza.
The New England journal of medicine 2004;351(24):2550-1.
2004: Robert B Belshe; Min-Shi Lee; Robert E Walker; Jeffrey J Stoddard; Paul M Mendelman
Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.
Expert review of vaccines 2004;3(6):643-54.
2004: Robert B Belshe; Frances K Newman; Joan Cannon; Carol Duane; John Treanor; Christian Van Hoecke; Barbara J Howe; Gary Dubin
Serum antibody responses after intradermal vaccination against influenza.
The New England journal of medicine 2004;351(22):2286-94.
2004: Robert B Belshe; Kristin L Nichol; Steven B Black; Henry Shinefield; Julie M Cordova; Robert E Walker; Colin Hessel; Iksung Cho; Paul M Mendelman
Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(7):920-7.
2004: Jeffrey S Kennedy; Sharon E Frey; Lihan Yan; Alan L Rothman; John Cruz; Frances K Newman; Laura Orphin; Robert B Belshe; Irene Bosch
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.
The Journal of infectious diseases 2004;190(7):1286-94.
2004: Deborah Lee; Barney S Graham; Ya-Lin Chiu; Peter B Gilbert; M Juliana McElrath; Robert B Belshe; Susan P Buchbinder; Haynes W Sheppard; Beryl A Koblin; Kenneth H Mayer; Michael C Keefer; Mark MULLIGAN; Connie Celum
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
The Journal of infectious diseases 2004;190(5):903-7.
2004: Robert B Belshe; Genoveffa Franchini; Marc P Girard; Frances Gotch; Pontiano Kaleebu; Marta L Marthas; Michael B McChesney; Rose McCullough; Fred Mhalu; Dominique Salmon-Ceron; Rafick-Pierre Sekaly; Koen K A Van Rompay; Bernard Verrier; Britta Wahren; Mercedes Weissenbacher
Support for the RV144 HIV vaccine trial.
Science (New York, N.Y.) 2004;305(5681):177-80; author reply 177-80.
2004: Robert B Belshe
Current status of live attenuated influenza virus vaccine in the US.
Virus research 2004;103(1-2):177-85.
2004: Kenneth M Zangwill; Robert B Belshe
Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination.
The Pediatric infectious disease journal 2004;23(3):189-97.
2004: Robert B Belshe; Frances K Newman; Sharon E Frey; Robert B Couch; John Treanor; Carol O Tacket; Lihan Yan
Dose-dependent neutralizing-antibody responses to vaccinia.
The Journal of infectious diseases 2004;189(3):493-7.
2004: Robert B Belshe; Frances K Newman; Theodore F Tsai; Ruth A Karron; Keith S Reisinger; Don Roberton; Helen Marshall; Richard Schwartz; James C King; Frederick W Henderson; William Rodriguez; Joseph M Severs; Peter F Wright; Harry Keyserling; Geoffrey A Weinberg; Kenneth Bromberg; Richard Loh; Peter Sly; Peter McIntyre; John B Ziegler; Jill Hackell; Anne M Deatly; Alice Georgiu; Maribel Paschalis; Shin-Lu Wu; Joanne M Tatem; Brian Murphy; Edwin Anderson
Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
The Journal of infectious diseases 2004;189(3):462-70.
2004: Frederick G Hayden; Robert B Belshe; Catalina Villanueva; Riin Lanno; Claire Hughes; Ian Small; Regina Dutkowski; Penelope Ward; Jackie Carr
Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.
The Journal of infectious diseases 2004;189(3):440-9.
2004: Sharon E Frey; Robert B Belshe
Poxvirus zoonoses--putting pocks into context.
The New England journal of medicine 2004;350(4):324-7.
2004: Geoffrey J Gorse; Gira B Patel; J Alan Arbuckle; Robert B Belshe
Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection.
Vaccine 2004;22(3-4):383-97.
2003: Robert B Belshe; Paul M Mendelman
Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent.
Immunology and allergy clinics of North America 2003;23(4):745-67.
2003: Frances K Newman; Sharon E Frey; Tamara P Blevins; Mahendra D Mandava; Andres Bonifacio; Lihan Yan; Robert B Belshe
Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine.
Journal of clinical microbiology 2003;41(7):3154-7.
2003: Sharon E Frey; Frances K Newman; Lihan Yan; Kathleen R Lottenbach; Robert B Belshe
Response to smallpox vaccine in persons immunized in the distant past.
JAMA : the journal of the American Medical Association 2003;289(24):3295-9.
2003: Ruth A Karron; Robert B Belshe; Peter F Wright; Bhagvanji Thumar; Barbars Burns; Frances K Newman; Joan C Cannon; Juliette Thompson; Theodore Tsai; Maribel Paschalis; Shin-Lu Wu; Yvonne Mitcho; Jill Hackell; Brian Murphy; Joanne M Tatem
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
The Pediatric infectious disease journal 2003;22(5):394-405.
2003: Frances K Newman; Sharon E Frey; Tamara P Blevins; Lihan Yan; Robert B Belshe
Stability of undiluted and diluted vaccinia-virus vaccine, Dryvax.
The Journal of infectious diseases 2003;187(8):1319-22.
2003: David I Bernstein; Lihan Yan; John Treanor; Paul M Mendelman; Robert B Belshe
Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines on antibody responses in children.
The Pediatric infectious disease journal 2003;22(1):28-34.
2002: Robert B Belshe; Robert B Couch; W Paul Glezen; John T Treanor
Live attenuated intranasal influenza vaccine.
Vaccine 2002;20(29-30):3429-30.
2002: Pedro Piedra; Lihan Yan; Karen L Kotloff; Kenneth M Zangwill; David I Bernstein; James C King; John Treanor; Flor M Munoz; Mark Wolff; Iksung Cho; Paul M Mendelman; Julie M Cordova; Robert B Belshe
Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children.
Pediatrics 2002;110(4):662-72.
2002: Sharon E Frey; Robert B Couch; Carol O Tacket; John Treanor; Mark Wolff; Frances K Newman; Robert L Atmar; Robert Edelman; Carrie M Nolan; Robert B Belshe
Clinical responses to undiluted and diluted smallpox vaccine.
The New England journal of medicine 2002;346(17):1265-74.
2002: Sharon E Frey; Frances K Newman; John Cruz; W Brian Shelton; Janice M Tennant; Tamara Polach; Alan L Rothman; Jeffrey S Kennedy; Mark Wolff; Robert B Belshe; Irene Bosch
Dose-related effects of smallpox vaccine.
The New England journal of medicine 2002;346(17):1275-80.
2002: John Treanor; Wendy A Keitel; Robert B Belshe; James D Campbell; Gilbert M Schiff; Kenneth M Zangwill; Mark Wolff; Alexander Klimov; Roland A Levandowski; Linda Lambert
Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.
Vaccine 2002;20(7-8):1099-105.
2001: Robert B Belshe; William C Gruber
Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2001;356(1416):1947-51.
2001: James C King; Patricia Fast; Kenneth M Zangwill; G A Weinberg; Mark Wolff; Lihan Yan; Frances K Newman; Robert B Belshe; Andrea Kovacs; J G Deville; M Jelonek
Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
The Pediatric infectious disease journal 2001;20(12):1124-31.
2001: Shewangizaw Worku; Geoffrey J Gorse; Robert B Belshe; Daniel F Hoft
Canarypox vaccines induce antigen-specific human gammadelta T cells capable of interferon-gamma production.
The Journal of infectious diseases 2001;184(5):525-32.
2001: Geoffrey J Gorse; Gira B Patel; Robert B Belshe
HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
AIDS research and human retroviruses 2001;17(12):1175-89.
2001: BR Luce; Kenneth M Zangwill; Cynthia S Palmer; Paul M Mendelman; Lihan Yan; M C Wolff; Iksung Cho; S Michael Marcy; D Iacuzio; Robert B Belshe
Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.
Pediatrics 2001;108(2):E24.
2001: Ranjit Ray; Daniel F Hoft; Keith Meyer; R Brown; L Martin Lagging; Robert B Belshe
Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus.
Virus research 2001;75(2):147-54.
2001: Robert B Belshe; C Stevens; Geoffrey J Gorse; Susan Buchbinder; Kent J Weinhold; Haynes W Sheppard; Donald Stablein; S Self; James McNamara; Sharon Frey; J Flores; Jean-Louis Excler; M Klein; R E Habib; AM Duliege; Clayton D Harro; Lawrence Corey; Michael C Keefer; Mark MULLIGAN; P Wright; Connie Celum; Franklyn N Judson; K Mayer; David J McKirnan; Michael Marmor; George E Woody
Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
The Journal of infectious diseases 2001;183(9):1343-52.
2001: Thomas G Evans; M Juliana McElrath; T Matthews; David Montefiori; Kent J Weinhold; Mark Wolff; Michael C Keefer; Esper Kallas; Lawrence Corey; Geoffrey J Gorse; Robert B Belshe; Barney S Graham; Paul Spearman; David H Schwartz; Mark MULLIGAN; Paul A Goepfert; Patricia Fast; Phillip W. Berman; M Powell; D Francis
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.
Vaccine 2001;19(15-16):2080-91.
2001: Geoffrey J Gorse; Gira B Patel; Mahendra D Mandava; J A Arbuckle; Timothy M Doyle; Robert B Belshe
Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120.
Vaccine 2001;19(13-14):1806-19.
2000: F Verrier; Sherri Burda; Robert B Belshe; AM Duliege; Jean-Louis Excler; M Klein; Susan Zolla-Pazner
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
Journal of virology 2000;74(21):10025-33.
2000: Peter F Wright; Ruth A Karron; Robert B Belshe; Juliette Thompson; James Crowe; Thomas G Boyce; L L Halburnt; George W Reed; Stephen S Whitehead; Edwin L Anderson; A E Wittek; Roberta Casey; Maryna C Eichelberger; Bhagvanji Thumar; Valerie B Randolph; Stephen A Udem; Robert M Chanock; Brian Murphy
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.
The Journal of infectious diseases 2000;182(5):1331-42.
2000: Steffanie Sabbaj; Mark MULLIGAN; RH Hsieh; Robert B Belshe; Jerry R McGhee
Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 2000;14(10):1365-74.
2000: M Juliana McElrath; Lawrence Corey; David Montefiori; Mark Wolff; David H Schwartz; Michael C Keefer; Robert B Belshe; Barney S Graham; T Matthews; P Wright; Geoffrey J Gorse; Raphael Dolin; Phillip W. Berman; D Francis; AM Duliege; Dani P Bolognesi; Donald Stablein; N Ketter; Patricia Fast
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 2000;16(9):907-19.
2000: Daniel F Hoft; Robin M Brown; Robert B Belshe
Mucosal bacille calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30 Suppl 3():S217-22.
2000: Robert B Belshe; William C Gruber
Prevention of otitis media in children with live attenuated influenza vaccine given intranasally.
The Pediatric infectious disease journal 2000;19(5 Suppl):S66-71.
2000: Ira M Longini; M Elizabeth Halloran; Azhar Nizam; Mark Wolff; Paul M Mendelman; Patricia Fast; Robert B Belshe
Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.
Vaccine 2000;18(18):1902-9.
2000: Robert B Belshe; William C Gruber; Paul M Mendelman; Hersh Mehta; Kutubuddin Mahmood; Keith S Reisinger; John Treanor; Kenneth M Zangwill; FG Hayden; David I Bernstein; Karen L Kotloff; James C King; Pedro Piedra; S L Block; Lihan Yan; Mark Wolff
Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
The Journal of infectious diseases 2000;181(3):1133-7.
2000: James C King; John Treanor; Patricia Fast; Mark Wolff; Lihan Yan; D Iacuzio; Bernard X Readmond; D O'Brien; Kenneth P Mallon; W Edward Highsmith; John S Lambert; Robert B Belshe
Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
The Journal of infectious diseases 2000;181(2):725-8.
2000: Robert B Belshe; William C Gruber; Paul M Mendelman; Iksung Cho; Keith S Reisinger; S L Block; Janet Wittes; D Iacuzio; Pedro Piedra; John Treanor; James C King; Karen L Kotloff; David I Bernstein; FG Hayden; Kenneth M Zangwill; Lihan Yan; Mark Wolff
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
The Journal of pediatrics 2000;136(2):168-75.
1999: John Treanor; Karen L Kotloff; Robert F Betts; Robert B Belshe; Frances K Newman; D Iacuzio; Janet Wittes; M Bryant
Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses.
Vaccine 1999;18(9-10):899-906.
1999: Geoffrey J Gorse; Gira B Patel; Mahendra D Mandava; Robert B Belshe
Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.
Vaccine 1999;18(9-10):835-49.
1999: Daniel F Hoft; E B Kemp; M Marinaro; O Cruz; H Kiyono; J R McGhee; John Belisle; T W Milligan; Philip Miller; Robert B Belshe
A double-blind, placebo-controlled study of Mycobacterium-specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination.
The Journal of laboratory and clinical medicine 1999;134(3):244-52.
1999: Kristin L Nichol; Paul M Mendelman; Kenneth P Mallon; Lisa A Jackson; Geoffrey J Gorse; Robert B Belshe; W P Glezen; Janet Wittes
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
JAMA : the journal of the American Medical Association 1999;282(2):137-44.
1999: Geoffrey J Gorse; Gira B Patel; Mahendra D Mandava; Phillip W. Berman; Robert B Belshe
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
AIDS research and human retroviruses 1999;15(10):921-30.
1999: Geoffrey J Gorse; Lawrence Corey; Gira B Patel; Mahendra D Mandava; RH Hsieh; TJ Matthews; MC Walker; M Juliana McElrath; Phillip W. Berman; M M Eibl; Robert B Belshe
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 1999;15(2):115-32.
1998: Robert B Belshe; Geoffrey J Gorse; Mark MULLIGAN; Thomas G Evans; Michael C Keefer; Jean-Louis Excler; AM Duliege; Jim Tartaglia; W I Cox; James McNamara; K L Hwang; A Bradney; David Montefiori; Kent J Weinhold
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
AIDS (London, England) 1998;12(18):2407-15.
1998: Donald P Francis; TJ Gregory; M Juliana McElrath; Robert B Belshe; Geoffrey J Gorse; Sricharoen Migasena; Dwip Kitayaporn; P Pitisuttitham; T Matthews; David H Schwartz; Phillip W. Berman
Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.
AIDS research and human retroviruses 1998;14 Suppl 3():S325-31.
1998: D M Granoff; R K Gupta; Robert B Belshe; Edwin L Anderson
Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination.
The Journal of infectious diseases 1998;178(3):870-4.
1998: Robert B Belshe; Paul M Mendelman; John Treanor; James C King; William C Gruber; Pedro Piedra; David I Bernstein; FG Hayden; Karen L Kotloff; Kenneth M Zangwill; D Iacuzio; Mark Wolff
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
The New England journal of medicine 1998;338(20):1405-12.
1998: James C King; Rosanna Lagos; David I Bernstein; Pedro Piedra; Karen L Kotloff; M Bryant; Iksung Cho; Robert B Belshe
Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children.
The Journal of infectious diseases 1998;177(5):1394-7.
1998: Mary Lou Clements-Mann; Kent J Weinhold; TJ Matthews; Barney S Graham; Geoffrey J Gorse; Michael C Keefer; M Juliana McElrath; RH Hsieh; Jiri Mestecky; Susan Zolla-Pazner; J Mascola; David H Schwartz; Robert Siliciano; Lawrence Corey; Peter F Wright; Robert B Belshe; Raphael Dolin; S Jackson; S Xu; Patricia Fast; MC Walker; Donald Stablein; Jean-Louis Excler; Jim Tartaglia; E Paoletti
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1998;177(5):1230-46.
1998: Geoffrey J Gorse; M Juliana McElrath; TJ Matthews; RH Hsieh; Robert B Belshe; Lawrence Corey; Sharon E Frey; Donald J Kennedy; MC Walker; M M Eibl
Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Vaccine 1998;16(5):493-506.
1998: Robert B Belshe
Influenza as a zoonosis: how likely is a pandemic?
Lancet 1998;351(9101):460-1.
1998: Barney S Graham; M Juliana McElrath; Ruth I Connor; David H Schwartz; Geoffrey J Gorse; Michael C Keefer; Mark MULLIGAN; TJ Matthews; Steven Wolinsky; David C Montefiori; Sten Vermund; John S Lambert; Lawrence Corey; Robert B Belshe; Raphael Dolin; Peter F Wright; Bette T Korber; M C Wolff; Patricia Fast
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.
The Journal of infectious diseases 1998;177(2):310-9.
1997: Michael C Keefer; Mark Wolff; Geoffrey J Gorse; Barney S Graham; Lawrence Corey; Mary Lou Clements-Mann; N Verani-Ketter; S Erb; C M Smith; Robert B Belshe; LJ Wagner; M Juliana McElrath; David H Schwartz; Patricia Fast
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
AIDS research and human retroviruses 1997;13(14):1163-77.
1997: Susan Zolla-Pazner; C Alving; Robert B Belshe; Phillip W. Berman; Sherri Burda; P Chigurupati; M L Clements; AM Duliege; Jean-Louis Excler; Catarina E Hioe; J Kahn; M Juliana McElrath; S Sharpe; F Sinangil; K Steimer; MC Walker; N Wassef; S Xu
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.
The Journal of infectious diseases 1997;175(4):764-74.
1996: Geoffrey J Gorse; E Y Yang; Robert B Belshe; Phillip W. Berman
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.
Clinical and diagnostic laboratory immunology 1996;3(6):769-73.
1996: Geoffrey J Gorse; Gira B Patel; F K Newman; Robert B Belshe; Phillip W. Berman; T J Gregory; TJ Matthews
Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
Clinical and diagnostic laboratory immunology 1996;3(4):378-86.
1996: E B Kemp; Robert B Belshe; Daniel F Hoft
Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin.
The Journal of infectious diseases 1996;174(1):113-9.
1996: John Treanor; R F Betts; G E Smith; E L Anderson; C S Hackett; B E Wilkinson; Robert B Belshe; D C Powers
Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.
The Journal of infectious diseases 1996;173(6):1467-70.
1996: William C Gruber; Robert B Belshe; James C King; John Treanor; Pedro Piedra; Peter F Wright; George W Reed; E Anderson; F Newman
Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.
The Journal of infectious diseases 1996;173(6):1313-9.
1996: John R Mascola; Stuart Snyder; O S Weislow; S M Belay; Robert B Belshe; David H Schwartz; M L Clements; Raphael Dolin; Barney S Graham; Geoffrey J Gorse; Michael C Keefer; M Juliana McElrath; MC Walker; K F Wagner; John G McNeil; Francine E McCutchan; Donald S. Burke
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1996;173(2):340-8.
1996: Geoffrey J Gorse; Michael C Keefer; Robert B Belshe; TJ Matthews; B D Forrest; RH Hsieh; W C Koff; Carl Hanson; Raphael Dolin; Kent J Weinhold; Sharon E Frey; N Ketter; Patricia Fast
A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
The Journal of infectious diseases 1996;173(2):330-9.
1995: Robert B Belshe
A review of attenuation of influenza viruses by genetic manipulation.
American journal of respiratory and critical care medicine 1995;152(4 Pt 2):S72-5.
1995: Geoffrey J Gorse; Gira B Patel; F K Newman; Mahendra D Mandava; Robert B Belshe
Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1995;13(13):1170-9.
1995: L M Lagging; Keith Meyer; Daniel F Hoft; Michael Houghton; Robert B Belshe; Ranjit Ray
Immune responses to plasmid DNA encoding the hepatitis C virus core protein.
Journal of virology 1995;69(9):5859-63.
1995: D C Powers; G E Smith; E L Anderson; D J Kennedy; C S Hackett; B E Wilkinson; F Volvovitz; Robert B Belshe; John Treanor
Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.
The Journal of infectious diseases 1995;171(6):1595-9.
1995: Ranjit Ray; Keith Meyer; F K Newman; Robert B Belshe
Characterization of a live, attenuated human parainfluenza type 3 virus candidate vaccine strain.
Journal of virology 1995;69(3):1959-63.
1995: Geoffrey J Gorse; J H Rogers; J E Perry; F K Newman; Sharon E Frey; Gira B Patel; Robert B Belshe
HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1995;13(2):209-14.
1994: Michael C Keefer; Barney S Graham; Robert B Belshe; David H Schwartz; Lawrence Corey; Dani P Bolognesi; Donald Stablein; D C Montefiori; M Juliana McElrath; M L Clements
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
AIDS research and human retroviruses 1994;10(12):1713-23.
1994: Geoffrey J Gorse; David H Schwartz; B S Graham; TJ Matthews; D M Stablein; Sharon E Frey; Robert B Belshe; M L Clements; P F Wright; M Eibl
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.
Clinical and experimental immunology 1994;98(2):178-84.
1994: Robert B Belshe; M L Clements; Michael C Keefer; Barney S Graham; L Corey; R Sposto; S Wescott; D Lawrence
Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group.
Annals of internal medicine 1994;121(8):584-9.
1994: Barney S Graham; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; M Juliana McElrath; TJ Matthews; Peter F Wright; Robert B Belshe; M L Clements; Raphael Dolin
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1994;170(4):782-6.
1994: Robert B Belshe; Barney S Graham; Michael C Keefer; Geoffrey J Gorse; P Wright; Raphael Dolin; T Matthews; Kent J Weinhold; Dani P Bolognesi; R Sposto
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
JAMA : the journal of the American Medical Association 1994;272(6):475-80.
1994: E L Anderson; T Bowers; C M Mink; D J Kennedy; Robert B Belshe; H Harakeh; LB Pais; P Holder; George M Carlone
Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults.
Infection and immunity 1994;62(8):3391-5.
1994: Geoffrey J Gorse; Sharon E Frey; G Patel; F K Newman; Robert B Belshe
Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1994;12(10):912-8.
1994: T U Westblom; S Gudipati; C DeRousse; B R Midkiff; Robert B Belshe
Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule.
The Journal of infectious diseases 1994;169(5):996-1001.
1994: D C Powers; Robert B Belshe
Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin".
The Journal of infectious diseases 1994;169(5):1125-9.
1994: E M Swierkosz; F K Newman; E L Anderson; S L Nugent; G B Mills; Robert B Belshe
Multidose, live attenuated, cold-recombinant, trivalent influenza vaccine in infants and young children.
The Journal of infectious diseases 1994;169(5):1121-4.
1994: Ruth A Karron; J L Froehlich; LD Bobo; Robert B Belshe; Robert H Yolken
Rapid detection of parainfluenza virus type 3 RNA in respiratory specimens: use of reverse transcription-PCR-enzyme immunoassay.
Journal of clinical microbiology 1994;32(2):484-8.
1994: E L Anderson; C M Mink; B S Berlin; C N Shih; F F Tung; Robert B Belshe
Acellular pertussis vaccines in infants: evaluation of single component and two-component products.
Vaccine 1994;12(1):28-31.
1994: Michael C Keefer; Robert B Belshe; B Graham; J McElrath; M L Clements; R Sposto; Patricia Fast
Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. NIAID AIDS Vaccine Clinical Trials Network.
AIDS research and human retroviruses 1994;10 Suppl 2():S139-40.
1993: E L Anderson; P R Becherer; Robert B Belshe
Revaccination with pneumococcal and hepatitis B vaccines.
JAMA : the journal of the American Medical Association 1993;270(22):2735-6.
1993: Robert B Belshe; M L Clements; Raphael Dolin; Barney S Graham; J McElrath; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; P Wright; L Corey
Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
The Journal of infectious diseases 1993;168(6):1387-95.
1993: Robert B Belshe; E L Anderson; E E Walsh
Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.
The Journal of infectious diseases 1993;168(4):1024-9.
1993: David H Schwartz; Geoffrey J Gorse; M L Clements; Robert B Belshe; Allen E Izu; AM Duliege; P Berman; T Twaddell; Donald Stablein; R Sposto
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.
Lancet 1993;342(8863):69-73.
1993: D C Powers; Robert B Belshe
Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine.
The Journal of infectious diseases 1993;167(3):584-92.
1993: Barney S Graham; TJ Matthews; Robert B Belshe; M L Clements; Raphael Dolin; Peter F Wright; Geoffrey J Gorse; David H Schwartz; Michael C Keefer; Dani P Bolognesi
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1993;167(3):533-7.
1992: Geoffrey J Gorse; Sharon E Frey; F K Newman; Robert B Belshe
Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Journal of clinical microbiology 1992;30(10):2606-12.
1992: E L Anderson; F K Newman; H F Maassab; Robert B Belshe
Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children.
Journal of clinical microbiology 1992;30(9):2230-4.
1992: Barney S Graham; Robert B Belshe; M L Clements; Raphael Dolin; Lawrence Corey; Peter F Wright; Geoffrey J Gorse; K Midthun; Michael C Keefer; N J Roberts
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.
The Journal of infectious diseases 1992;166(2):244-52.
1992: Robert B Belshe; Ruth A Karron; F K Newman; E L Anderson; S L Nugent; mark steinhoff; M L Clements; Modena E H Wilson; S L Hall; E L Tierney
Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children.
Journal of clinical microbiology 1992;30(8):2064-70.
1992: Robert B Belshe; E M Swierkosz; E L Anderson; F K Newman; S L Nugent; H F Maassab
Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine.
The Journal of infectious diseases 1992;165(4):727-32.
1992: S L Hall; A Stokes; E L Tierney; W T London; Robert B Belshe; F C Newman; Brian Murphy
Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys.
Virus research 1992;22(3):173-84.
1992: Geoffrey J Gorse; Robert B Belshe; F K Newman; Sharon E Frey
Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.
Vaccine 1992;10(6):383-8.
1991: M L Clements; Robert B Belshe; James C King; F Newman; T U Westblom; E L Tierney; W T London; Brian Murphy
Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.
Journal of clinical microbiology 1991;29(6):1175-82.
1991: R Dolin; Barney S Graham; S B Greenberg; Carol O Tacket; Robert B Belshe; K Midthun; M L Clements; Geoffrey J Gorse; B W Horgan; Robert L Atmar
The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.
Annals of internal medicine 1991;114(2):119-27.
1988: Neal A Halsey; E L Anderson; S D Sears; mark steinhoff; Modena E H Wilson; Robert B Belshe; K Midthun; Albert Z Kapikian; Robert M Chanock; R Samorodin
Human-rhesus reassortant rotavirus vaccines: safety and immunogenicity in adults, infants, and children.
The Journal of infectious diseases 1988;158(6):1261-7.